vs
DYNEX CAPITAL INC（DX）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是DYNEX CAPITAL INC的1.7倍（$75.5M vs $43.5M），DYNEX CAPITAL INC同比增速更快（531.3% vs 27.7%），过去两年DYNEX CAPITAL INC的营收复合增速更高（75.8% vs 31.3%）
Dynex Capital Inc是一家总部位于美国的上市房地产投资信托公司，专注于投资和管理抵押贷款支持证券、住宅及商业抵押贷款等各类抵押相关资产组合，通过稳健运营为股东创造稳定分红和长期资本增值。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
DX vs PBYI — 直观对比
营收规模更大
PBYI
是对方的1.7倍
$43.5M
营收增速更快
DX
高出503.6%
27.7%
两年增速更快
DX
近两年复合增速
31.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $43.5M | $75.5M |
| 净利润 | — | — |
| 毛利率 | — | 69.3% |
| 营业利润率 | — | 22.7% |
| 净利率 | — | — |
| 营收同比 | 531.3% | 27.7% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $1.59 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DXPBYI
| Q4 25 | $43.5M | $75.5M | ||
| Q3 25 | $30.6M | $54.5M | ||
| Q2 25 | $23.1M | $52.4M | ||
| Q1 25 | $17.1M | $46.0M | ||
| Q4 24 | — | $59.1M | ||
| Q3 24 | — | $80.5M | ||
| Q2 24 | — | $47.1M | ||
| Q1 24 | $-3.2M | $43.8M |
净利润DXPBYI
| Q4 25 | — | — | ||
| Q3 25 | $150.4M | $8.8M | ||
| Q2 25 | $-13.6M | $5.9M | ||
| Q1 25 | $-3.1M | $3.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $20.3M | ||
| Q2 24 | — | $-4.5M | ||
| Q1 24 | $40.1M | $-4.8M |
毛利率DXPBYI
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
营业利润率DXPBYI
| Q4 25 | — | 22.7% | ||
| Q3 25 | — | 17.6% | ||
| Q2 25 | — | 12.7% | ||
| Q1 25 | — | 8.7% | ||
| Q4 24 | — | 22.6% | ||
| Q3 24 | — | 27.4% | ||
| Q2 24 | — | -4.6% | ||
| Q1 24 | — | -5.3% |
净利率DXPBYI
| Q4 25 | — | — | ||
| Q3 25 | 491.3% | 16.2% | ||
| Q2 25 | -58.8% | 11.2% | ||
| Q1 25 | -18.0% | 6.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 25.2% | ||
| Q2 24 | — | -9.6% | ||
| Q1 24 | -1256.8% | -11.0% |
每股收益（稀释后）DXPBYI
| Q4 25 | $1.59 | $0.26 | ||
| Q3 25 | $1.08 | $0.17 | ||
| Q2 25 | $-0.14 | $0.12 | ||
| Q1 25 | $-0.06 | $0.06 | ||
| Q4 24 | — | $0.40 | ||
| Q3 24 | — | $0.41 | ||
| Q2 24 | — | $-0.09 | ||
| Q1 24 | $0.64 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $531.0M | $97.5M |
| 总债务越低越好 | — | $22.7M |
| 股东权益账面价值 | $2.5B | $130.3M |
| 总资产 | $17.3B | $216.3M |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资DXPBYI
| Q4 25 | $531.0M | $97.5M | ||
| Q3 25 | $491.0M | $94.4M | ||
| Q2 25 | $387.5M | $96.0M | ||
| Q1 25 | $327.4M | $93.2M | ||
| Q4 24 | — | $101.0M | ||
| Q3 24 | — | $96.7M | ||
| Q2 24 | — | $96.8M | ||
| Q1 24 | $295.7M | $107.2M |
总债务DXPBYI
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
股东权益DXPBYI
| Q4 25 | $2.5B | $130.3M | ||
| Q3 25 | $2.0B | $115.3M | ||
| Q2 25 | $1.6B | $104.7M | ||
| Q1 25 | $1.4B | $97.1M | ||
| Q4 24 | — | $92.1M | ||
| Q3 24 | — | $71.1M | ||
| Q2 24 | — | $48.5M | ||
| Q1 24 | $958.5M | $51.0M |
总资产DXPBYI
| Q4 25 | $17.3B | $216.3M | ||
| Q3 25 | $14.2B | $202.9M | ||
| Q2 25 | $11.3B | $194.9M | ||
| Q1 25 | $9.0B | $196.2M | ||
| Q4 24 | — | $213.3M | ||
| Q3 24 | — | $220.7M | ||
| Q2 24 | — | $205.0M | ||
| Q1 24 | $6.3B | $214.1M |
负债/权益比DXPBYI
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $120.8M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | — | $14.4M |
| 自由现金流率自由现金流/营收 | — | 19.1% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $41.7M |
8季度趋势，按日历期对齐
经营现金流DXPBYI
| Q4 25 | $120.8M | $14.4M | ||
| Q3 25 | $68.3M | $9.7M | ||
| Q2 25 | $31.9M | $14.1M | ||
| Q1 25 | $6.4M | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | — | $1.0M | ||
| Q1 24 | $-17.1M | $11.2M |
自由现金流DXPBYI
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | — | $1.0M | ||
| Q1 24 | — | — |
自由现金流率DXPBYI
| Q4 25 | — | 19.1% | ||
| Q3 25 | — | 17.7% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | — |
资本支出强度DXPBYI
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
现金转化率DXPBYI
| Q4 25 | — | — | ||
| Q3 25 | 0.45× | 1.10× | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.43× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
